Guggenheim Starts Neothetics Inc. (NEOT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
Needham & Company Starts Neothetics Inc. (NEOT) at Buy
December 15, 2014 6:41 AM ESTNeedham & Company initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Buy rating and a price target of $17.00.
Analyst Elliot Wilbur commented, "We initiate coverage of Neothetics (NEOT), a clinical-stage specialty pharma company focused on developing and commercializing innovative and differentiated... More
Piper Jaffray Starts Neothetics Inc. (NEOT) at Overweight
December 15, 2014 6:39 AM ESTPiper Jaffray initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Overweight rating and a price target of $20.00.
Analyst David Amsellem comments, "NEOT, in our view, is well positioned to expand and transform the emerging body contouring space with LIPO-202, an injectable form... More
